<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="374">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04639050</url>
  </required_header>
  <id_info>
    <org_study_id>BP42155</org_study_id>
    <secondary_id>2020-002477-98</secondary_id>
    <nct_id>NCT04639050</nct_id>
  </id_info>
  <brief_title>Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease</brief_title>
  <official_title>A Phase Ib/IIa, Randomized, Double Blind, Placebo-Controlled, Multiple Ascending Dose, Parallel-Group Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Patients With Prodromal or Mild to Moderate Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, immunogenicity,&#xD;
      pharmacokinetics, and pharmacodynamics of multiple-ascending intravenous (IV) doses of&#xD;
      RO7126209 in participants with prodromal or mild to moderate Alzheimer's disease (AD), who&#xD;
      are amyloid positive based on amyloid positron emission tomography (PET) scan.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 15, 2021</start_date>
  <completion_date type="Anticipated">October 3, 2024</completion_date>
  <primary_completion_date type="Anticipated">October 3, 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Adverse Events (AEs), Including Dose-Limiting Adverse Events (DLAEs)</measure>
    <time_frame>Up to 56 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Brain Amyloid Load as Measured by Amyloid Positron Emission Tomography (PET) Scan</measure>
    <time_frame>Baseline, Week 12 (Cohorts 3 and 4 only), Week 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration of RO7126209</measure>
    <time_frame>Up to 32 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebral Spinal Fluid (CSF) Concentration of RO7126209</measure>
    <time_frame>Baseline, Week 25</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Anti-Drug Antibodies (ADAs) to RO7126209</measure>
    <time_frame>Up to 56 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Alzheimers Disease</condition>
  <arm_group>
    <arm_group_label>Cohort 1: Dose Level 1 of RO7126209</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive multiple doses of RO7126209 at dose level 1 once every 4 weeks (Q4W) for 28 weeks followed by a 28-week safety follow-up period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive matching placebo to dose level 1 Q4W for 28 weeks followed by a 28-week safety follow-up period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: Dose Level 2 of RO7126209</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive multiple doses of RO7126209 at dose level 2 once every 4 weeks (Q4W) for 28 weeks followed by a 28-week safety follow-up period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive matching placebo to dose level 2 Q4W for 28 weeks followed by a 28-week safety follow-up period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: Dose Level 3 of RO7126209</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive multiple doses of RO7126209 at dose level 3 once every 4 weeks (Q4W) for 28 weeks followed by a 28-week safety follow-up period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive matching placebo to dose level 3 Q4W for 28 weeks followed by a 28-week safety follow-up period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort : Dose Level 4 of RO7126209</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive multiple doses of RO7126209 at dose level 4 once every 4 weeks (Q4W) for 28 weeks followed by a 28-week safety follow-up period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive matching placebo to dose level 4 Q4W for 28 weeks followed by a 28-week safety follow-up period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RO7126209</intervention_name>
    <description>RO7126209 will be administered via intravenous (IV) infusion, Q4W for a total of seven doses during 28 weeks of treatment.</description>
    <arm_group_label>Cohort 1: Dose Level 1 of RO7126209</arm_group_label>
    <arm_group_label>Cohort 2: Dose Level 2 of RO7126209</arm_group_label>
    <arm_group_label>Cohort 3: Dose Level 3 of RO7126209</arm_group_label>
    <arm_group_label>Cohort : Dose Level 4 of RO7126209</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo will be administered via IV infusion, Q4W for a total of seven doses during 28 weeks of treatment.</description>
    <arm_group_label>Cohort 1: Placebo</arm_group_label>
    <arm_group_label>Cohort 2: Placebo</arm_group_label>
    <arm_group_label>Cohort 3: Placebo</arm_group_label>
    <arm_group_label>Cohort 4: Placebo</arm_group_label>
    <other_name>RO727-5887, F01-01</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key inclusion criteria:&#xD;
&#xD;
          -  Ability to provide written consent signed by the participant&#xD;
&#xD;
          -  Availability of a person (referred to as the &quot;study partner&quot;) who: consents to&#xD;
             participate throughout the duration of study, in the Investigator's judgment, has&#xD;
             frequent and sufficient contact with the participant, is fluent in the language of the&#xD;
             tests used at the study site&#xD;
&#xD;
          -  Willingness and ability to complete all aspects of the study (including Magnetic&#xD;
             resonance imaging [MRI], lumbar puncture, clinical genotyping, and positron emission&#xD;
             tomography [PET] imaging)&#xD;
&#xD;
          -  Capable of completing assessments either alone or with the help of the study partner&#xD;
&#xD;
          -  Adequate visual and auditory acuity, in the Investigator's judgment, sufficient to&#xD;
             perform the neuropsychological testing (eye glasses and hearing aids are permitted)&#xD;
&#xD;
          -  Probable mild to moderate Alzheimer's Disease (AD) dementia (consistent with National&#xD;
             Institute on Aging-Alzheimer's Association [NIA-AA] core clinical criteria for&#xD;
             probable AD dementia) or prodromal AD (consistent with the NIA-AA diagnostic criteria&#xD;
             and guidelines for mild cognitive impairment due to AD)&#xD;
&#xD;
          -  Screening Mini-Mental State Examination (MMSE) score of 18 to 28 points, inclusive,&#xD;
             within 3 months before baseline&#xD;
&#xD;
          -  Clinical Dementia Rating-Global Score (CDR-GS) of 0.5, 1, or 2 within 3 months before&#xD;
             baseline&#xD;
&#xD;
          -  Positive amyloid PET scan (cut-off: &gt;50 Centiloid units) within 12 months before&#xD;
             baseline&#xD;
&#xD;
          -  In case of treatment with symptomatic AD medications, dosing regimen must be stable&#xD;
             for at least 8 weeks prior to baseline and until randomization&#xD;
&#xD;
          -  Agreement not to donate blood or blood products for transfusion for the duration of&#xD;
             the study and for 1 year after final dose of study drug&#xD;
&#xD;
          -  Agreement not to participate in other research studies for the duration of this study&#xD;
&#xD;
          -  Agree to apolipoprotein E (APOE) genotyping&#xD;
&#xD;
        Key exclusion criteria:&#xD;
&#xD;
          -  Any evidence of other relevant neurological condition, including other (non-AD)&#xD;
             neurodegenerative and neuropsychiatric conditions, neurovascular brain disorders,&#xD;
             seizure disorders, inflammatory and infectious disorders of the central nervous&#xD;
             system, trauma and delirium, among several others&#xD;
&#xD;
          -  Other relevant medical conditions including significant hematological diseases, any&#xD;
             clinically significant ophthalmologic diseases, clinically significant cardiovascular&#xD;
             diseases, chronic kidney disease, confirmed and unexplained impaired hepatic function,&#xD;
             abnormal thyroid function, among several others&#xD;
&#xD;
          -  History of hypersensitivity to biologic agents or any of the excipients in the&#xD;
             formulation&#xD;
&#xD;
          -  Clinically significant abnormalities (as judged by the Investigator) in laboratory&#xD;
             test results (including complete blood count, chemistry panel, routine cerebrospinal&#xD;
             fluid [CSF] parameters and urinalysis)&#xD;
&#xD;
          -  MRI exclusion criteria: &gt;2 lacunar infarcts, any territorial infarct &gt;1 cm^3, any&#xD;
             white matter lesion that corresponds to an overall Fazekas score of 3 that requires at&#xD;
             least one confluent hyperintense lesion on the fluid-attenuated inversion recovery&#xD;
             (FLAIR) sequence, which is ≥20 mm in any dimension&#xD;
&#xD;
          -  Combined number of microhemorrhages and focal areas of leptomeningeal hemosiderosis&#xD;
             (i.e., cumulative amyloid-related imaging abnormality-microhemorrhage/hemosiderin&#xD;
             deposition [ARIA-H]) on MRI more than 5 (and should not include more than 3 focal&#xD;
             areas of leptomeningeal hemosiderosis) based on the review performed by the central&#xD;
             MRI reader prior to randomization&#xD;
&#xD;
          -  Presence of any other significant cerebral abnormalities, including amyloid-related&#xD;
             imaging abnormality-edema/effusion (ARIA-E), as assessed on MRI&#xD;
&#xD;
          -  Inability to tolerate MRI procedures or contraindication to MRI&#xD;
&#xD;
          -  Inability to undergo ophthalmological assessments&#xD;
&#xD;
          -  Contraindication to lumbar puncture&#xD;
&#xD;
          -  Contraindication to having a PET scan&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: BP42155 https://forpatients.roche.com/</last_name>
    <phone>888-662-6728 (U.S. Only)</phone>
    <email>global-roche-genentech-trials@gene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>JEM Research LLC</name>
      <address>
        <city>Atlantis</city>
        <state>Florida</state>
        <zip>33462</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Brain Matters Research, Inc.</name>
      <address>
        <city>Delray Beach</city>
        <state>Florida</state>
        <zip>33445</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Progressive Medical Research</name>
      <address>
        <city>Port Orange</city>
        <state>Florida</state>
        <zip>32127</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Quest Research Institute</name>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <zip>48334</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Abington Neurological Associates</name>
      <address>
        <city>Abington</city>
        <state>Pennsylvania</state>
        <zip>19001</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kerwin Research Center, LLC; Kerwin Research Center, LLC</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Heidelberg Repatriation Hospital; Medical and Cognitive Research Centre</name>
      <address>
        <city>Heidelberg West</city>
        <state>Victoria</state>
        <zip>3081</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alfred Hospital; Department of Neurology</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Osrodek Badan Klinicznych Euromedis</name>
      <address>
        <city>Szczecin</city>
        <zip>70-111</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NZOZ WCA</name>
      <address>
        <city>Wrocław</city>
        <zip>53-659</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital General De Catalunya; Servicio de Neurologia</name>
      <address>
        <city>Sant Cugat del Valles</city>
        <state>Barcelona</state>
        <zip>8195</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Fundación ACE; Servicio de Neurología</name>
      <address>
        <city>Barcelona</city>
        <zip>08028</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic i Provincial; Servicio de Neurologia</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Dr. Peset; Servicio de Neurologia</name>
      <address>
        <city>Valencia</city>
        <zip>46017</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 17, 2020</study_first_submitted>
  <study_first_submitted_qc>November 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2020</study_first_posted>
  <last_update_submitted>November 4, 2022</last_update_submitted>
  <last_update_submitted_qc>November 4, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 7, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

